isoproterenol has been researched along with bay 58-2667 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnucz, E; Hirschberg, K; Karck, M; Korkmaz, S; Loganathan, S; Neugebauer, P; Páli, S; Radovits, T; Seidel, B; Szabó, G; Veres, G; Zöllner, S | 1 |
| Busch, M; Busch, R; Dörr, M; Eckerle, LG; Felix, SB; Gross, S; Hertrich, I; Rauch, BH; Reinke, Y; Riad, A; Stasch, JP | 1 |
2 other study(ies) available for isoproterenol and bay 58-2667
| Article | Year |
|---|---|
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
Topics: Adrenergic beta-Agonists; Animals; Benzoates; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Cyclooxygenase 2; Dogs; Female; Gene Expression; Guanylate Cyclase; Heart Function Tests; Isoproterenol; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Survival Rate; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta1 | 2009 |
The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Topics: Animals; Benzoates; Calcium; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Drug Synergism; Electric Stimulation; Female; Guanylate Cyclase; Isoproterenol; Muscle Relaxation; Myocardial Contraction; Myocytes, Cardiac; Oxadiazoles; Pyrazoles; Pyrimidines; Quinoxalines; Rats; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Thionucleotides; Verapamil | 2015 |